Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0XYMVO)
ADC Name
Dara-VA-I034 (8)
Synonyms
Dara-VA-I034 (8)
   Click to Show/Hide
Drug Status
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Daratumumab
  Antibody Info 
Antigen Name
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
  Antigen Info 
Payload Name
I034
  Payload Info 
Payload Target
IKZF1/3
  Target Info 
Linker Name
MC-VA
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
99.94
%
Undisclosed Undisclosed
Tumor Growth Inhibition value (TGI) 
100
%
Undisclosed Undisclosed
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.00269
nM
CVCL_1600
Multiple myeloma
Half Maximal Inhibitory Concentration (IC50) 
0.00941
nM
CVCL_8792
Multiple myeloma
Half Maximal Inhibitory Concentration (IC50) 
> 50
nM
CVCL_0140
Normal
Half Maximal Degradation Concentration (DC50) 
0.075
nM
CVCL_1600
Multiple myeloma
Half Maximal Degradation Concentration (DC50) 
13.8
nM
CVCL_0140
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
99.94%
In Vivo Model NCI-H929 CDX 3 mpk (Day 25)
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
100%
In Vivo Model NCI-H929 CDX 6 mpk (Day25)
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.00269 nM
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.00941 nM
In Vitro Model Plasma cell myeloma, Multiple myeloma MM.1S cells CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 50 nM
In Vitro Model Normal PBMC cells CVCL_0140
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Degradation Concentration (DC50)
0.075 nM
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Degradation Concentration (DC50)
13.8 nM
In Vitro Model Normal PBMC cells CVCL_0140
References
Ref 1 Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy